Diagnosis and combined treatment of patients with locally advanced prostate cancer

Bibliography:
1. 1. Aksel' EM. Statistics malignancies in Russia and the CIS in 2008. Vestnik RONC im NN Blohina RAMN 2010; 21 (2), Application 1:160
2. Epidemiology of prostate cancer. In: Matveev BP, ed. Clinical oncourology. A Guide for Physicians. Moscow: Medicine, 2003: 435-440 p.
3. Aksel' ЕМ. Prostate Cancer. Moscow: Medicina, 2002; 1120 p.
4. Ahmedin J, Freddie В, Melissa MC, et al. Global Cancer Statistics. CA: Cancer Journal for Clinicians 2011; 61: 69-90
5. Veliev El. Hormone therapy for prostate cancer. Practical oncology 2008; 9 (2): 98-103
6. Boyle Р, Maisonneuve Р, Napalkov P. Incidence of prostate cancer will double by the year 2030: arguments. Europ J Urol 1996;29:3-9
7. Apolihin Ol, Sivkov AV, Moskaleva NG, Solnceva TV. Analysis of urological morbidity and mortality in the Russian Federation for the ten-year period 2002-2012 years according to official statistics. Experimental and clinical urology 2014; (2): 4-12
8. Zubkov AJu, Ataev RZ. Algorithm for the diagnosis, monitoring and treatment of prostate cancer. In: Topical issues of Urology: Materials jubilee scientific and practical conference devoted to the 100th anniversary of his clinic. A. B. Vishnevsky Kazan, 2000; p. 113-114
9. Veliev El. Hormone therapy for locally advanced and metastatic prostate cancer: current approaches. Practical oncology 2001; 2 (6): 38-41
10. Oncourology: national leadership. М: GJeOTAR-Media, 2012; 688 p.
11. Matveev BP, ed. Diagnosis of prostate cancer. In: Clinical oncourology. monograph for physicians. Moscow: Medicine, 2011: 561-565 p.
12. Pereverzev AC, Kogan Ml. Cancer Prostate. Har'kov, 2004; 231 p.
13. Schnall MD, et al. Prostate cancer:localstading with endorectal surface coil MR imaging. Radiology 1991; 178: 797-802
14. YamadaAH, et al. Results of radical prostatectomy and adjuvant therapy in the management of locally advanced,clinical stage TC, prostate cancer. J Clin Oncol 1994; Aug 17 (4): 277-85
15. Hsu CY, et al. Outcome of surgery for clinical unilateral T3a prostste cancer: a single-institution experience. Eur Urol 2007; 51 (1): 121-8
16. Ward JF, et al. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. В J U Int 2005; 95 (6): 751-756
17. Epstein Jl, CarMichael M, Walsh PS. Adenocarcinoma of the prostate invading the seminal vesicle: definition and relation of tumor volume, grade and margins of resection to prognosis. J Urol 1993; 149: 1040-1046
18. Loran OB, Tomkevich BA. Treatment for prostate cancer in stage T3NxMo. Urology 2004; (6): 5-67
19. Huggins С, Hodges С. Studies on prostate cancer: The effect of castration. Cancer Res 1941; 1: 293-297
20. Prostate cancer. In: Matveeva BP, ed. Clinical oncourology. Moscow: Verdal, 2003; p. 433-606
21. Transrectal color Doppler ultrasonography in patients with prostate cancer before and after orchiectomy. Proceedings of the Board of DOC 1999; 39-40
22. Letkovskaja ТА, Cherstvyj ED, Zaharova VA, Puchinskaja MV Neuroendocrine differentiation in prostate cancer: biological and prognostic value. Medical Journal 2007; 22 (4): 10-12
23. Glybochko PV, Popkov VM. Neuroendocrine aspects of carcinogenesis in the prostate gland. Saratov Journal of Medical Scientific Research 2010; 6 (1): 164-170
24. Kushlinskij NE, Solov'ev JuN, Trapeznikova MF. Prostate Cancer. M., 2002; 432 p.
25. Matveev BP Role casodex 50mg and 150mg in the treatment of advanced prostate cancer: Manual for physicians. M, 2001
26. Karjakin OB. Combined treatment of locally advanced prostate cancer and non-proliferation. In: 3 Materials of the Scientific Conference with the participation of the CIS countries "Actual problems of treatment of diseases oncourological". Moscow, 1999; p. 52-54
27. Arai Y, Yoshika Т, Voshida О. Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer. J Urol 1990; 44: 1415-1419
28. Matveeva BP, ed. Clinical oncourology. Moscow: Verdal, 2003; 717 p.
29. Loran OB, Pushkar' DJu, Frank GF. Prostate specific antigen and morphological characteristics of prostate cancer: A Guide for Physicians. Moscow, 1999; 143 p.
30. Matveev BP, Komarova LE, Buharkin BV Resultsof a 5-year screening prostate cancer. Urology 2003; (1): 6-9
31. Aljaev JuG, Aslamazov JeG, Demidko JuL. Hormone therapy for inoperable prostate cancer (the results of their 3-and 5-year observations). In: Materials V-th Russian conference "Actual problems of treatment of cancer", Obninsk, 2003; p. 16
32. Narayan Р, Lowe BA, Carrol P. Neoadjuyant hormonal therapy and radical prostatectomy for clinical stage С carcinoma of the prostate. Br J Urol 1994; (73): 548-554
33. Huggins C, Hodges CV. Studies on prostate cancer I: The effects of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. J Urol2002; 168(1): 9-12
34. Karjakin OB. Standards in the treatment of various stages of prostate cancer. Practical oncology 2001; 2 (6) 24-27
35. Liebel SA, Fuks Z, Zelefsky MJ, et al. The effects of local and regional treatments on the metastatic outcome in prostatic carcinoma with pelvic lymph node involvement. Int J Radiat Oncol Biol Phys 1994; 28 (1): 7-16
36. Horwitz EM, Hanks GE, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008; 26 (15): 2497-2504
37. D Amico AV, Loffredo M, Renshaw AA, et al. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pre-treatment prostate-specific antigen level. J Clin Oncol 2006; 24: 4190-4195
38. Roach M, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long term results of RTOG 8610. J Clin Oncol 2008; 26 (4): 585-591
39. Pilepich MV, Winter K, Roach M, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation before and during radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50: 1243-1252
40. Roach M, Lawton C, et al. Phase III trial campering whole-pelvic versus prostate-only radiotherapy and neoadjuvant combined androgen suppression: RTOG 9413. J Clinic Oncol 2003; 21 (10): 1904-1911
41. Zagars GK, Pollack A, Smith LG. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III T3No-xMo adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 1999; 44 (4): 809-819.